CA
NZ
UK
AU
IND
US
The Phase 3 EMERGE trial in generalized myasthenia gravis began in June 2026, with top-line results expected in the second half of 2028. The Phase 3 CAPTIVATE trial in chronic inflammatory demyelinating polyneuropathy reported a 75% response rate in an interim analysis of the …
Friedreich ataxia spending was USD 4.7 million in the quarter, while spending on the eye disease program fell to USD 0.5 million from USD 1.6 million. In May 2026 the company reported four-week data from its Phase 1/2 RESTORE-FA trial of DT-216P2, with a …
Key HighlightsNet sales for the quarter ended September 30, 2026 rose 12% to USD 9.7 million from USD 8.7 million, led by Quell Fibromyalgia and prescription gammaCore sold to the Veterans Affairs channel.Net loss narrowed to USD 1.3 million, or USD 0.13 per share, …
Key HighlightsDiluted earnings per share were USD 5.57 for the third quarter, up from USD 3.17 a year earlier, onNet Incomeof USD 124.0 million against USD 74.7 million.Total revenues rose 18.3% to USD 544.5 million, andDebtpurchasingRevenuerose 21.1% to USD 525.5 million as changes in …
Key HighlightsNet income was USD 60.0 million for the quarter ended September 30, 2026, against USD 55.0 million a year earlier, andDiluted Earnings per Sharewere USD 0.44 against USD 0.43.Revenues were USD 297.2 million, down about 24.0% (calculated) from USD 391.0 million, as LNG, …
LongbridgeNet Incomefell from USD 30.2 million in the second quarter, with narrower origination margins and lower proprietary securitization gains offsetting higher volumes. It originated USD 676.3 million of loans, up 36% year over year, and reached a record 31% share of the reverse mortgage …
Adjusted EBITDA was USD 24.9 million, a 13.0% margin, against USD 22.0 million and 12.0%. Cash provided byOperating Activitieswas USD 13.1 million against USD 8.8 million. Cash, cash equivalents and restricted cash were USD 102.6 million, while total debt principal fell to USD 309.4 …
Key HighlightsNet sales rose 51% to USD 520.8 million for the fiscal second quarter ended September 30, 2026, the company's 31st consecutive quarter of net sales growth.GAAPDiluted Earnings per Sharewere USD 0.50 onNet Incomeof USD 30.0 million, while adjusted diluted earnings per share were …
Key HighlightsNet revenues rose 13.0% to USD 78.0 million for the quarter ended September 30, 2026, from USD 69.0 million, on higher Jeuveau and Evolysse sales.Net loss narrowed to USD 12.5 million, or USD 0.19 per share, from USD 15.7 million, or USD 0.24, …
Cogent Communications Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 5, 2026, reporting a net loss of $29.8 million for the third quarter.
Please wait processing your request...